BIP Features »

May 20, 2020 – 7:00 am |

Over £64.8 million has been invested into 257 businesses by the Midlands Engine Investment Fund (MEIF), with new data revealing its regional impact released today (Wednesday 20 May 2020).
Go to the main page

Read the full story »
BIP business guides & tools

Please register/login to access content

BIP Access to Finance

Access to Finance,Grants & Business Support

BIP Features

West Midlands business highlights, opportunites and networking

Bips and Pieces

All the best from the web handpicked out by our team, including the World of tech

Business News

Latest West Midlands news affecting your business

Home » Business News

Welsh biomaterials start-up Mikota launches key products at Medica 2017…

Submitted by on November 15, 2017 – 6:00 am |

Mikota LogoMikota Ltd, a new Wales-based biotechnology and medical device company, will launch its two key products at the Medica trade show in Düsseldorf from 13 – 16 November 2017. It will also be giving away $500,000-worth of promotional product to researchers and companies interested in their use or development.

Based in Pembroke Dock, Mikota is harvesting slipper limpets from the Welsh coast and extracting their blood and purifying out hemocyanin for use as a protein adjuvant for the anti-cancer and immunology markets. The company is also extracting collagen from the limpets, making a range of products including solubilised, powder, sponge and fibrillar collagen. These collagen products can be used in a wide range of applications and medical devices, with uses including breast, bone and nerve reconstruction.

While hemocyanin has been extracted from other marine creatures, this is the first time that slipper limpets have been used in this way.

Harvesting the limpets also has environmental benefits. If slipper limpets colonise an area, they can create a toxic environment for other marine life. By developing a wide range of products that require volume harvesting of the limpets, Mikota will be clearing the way for a more balanced ecosystem, which includes reclaiming native oyster beds.

Mikota founder and CEO Alex Mühlhölzl explained:

“Slipper limpets can have a massive negative impact on the marine environment especially native oyster beds. By reducing their population we can inject new life into native oyster beds that have effectively died off and those that are under increasing pressure. This is another bonus of targeting invasive species. So, while we don’t directly get all the benefits, we can help other businesses improve and grow over time, which is the basis for one of the projects we are developing in Cornwall.

“Mikota is not just a biomaterials company; we are also developing a range of medical devices in the fields of regenerative medicine, advanced wound care, transected nerve repair and mastectomy/breast reconstruction, with a range of our own products and patents in development.

“With its thermal stability our collagen product, Maricoll, is the perfect material for developing new collagen based devices, as well as directly substituting into present bovine/porcine collagen formulations. Our hemocyanin, BioCyanin SLH, is a new protein adjuvant aimed at the high value anti-cancer and immunology markets. We are also planning to undertake a range of cell screening and research projects focused on those fields.”

Now Mikota is holding a massive $500,000 giveaway of products to anyone interested in investigating their uses.

“We believe in our products and want to form partnership and collaborations,” said Alex. “We are already working with Cardiff University and Collagen Solutions plc, our industry partner, and welcome approaches from anyone interested in using our products in research or collaborative projects.”

Anyone interested in receiving product should visit or meet the Mikota team at the Medica trade show and exhibition in Germany from November 13-16, Hall 16 Stand F42, where they will be officially launching their products.

Go to the main page

Tags: , , , , , , , , , ,

We use Cookies - By using this site or closing this you agree to our Cookies policy.
Accept Cookies